Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
CSPC PHARMA's Antibody-Drug Conjugate SYS 6041 Approved for US Clinical Trials
Recommend 7 Positive 12 Negative 7 |
||||
|
||||
|
CSPC PHARMA (01093.HK) announced that the Investigational New Drug (IND) application for SYS6041 (Antibody-Drug Conjugate) developed by the group has been approved by the US Food and Drug Administration (FDA) to conduct clinical trials in the US. The indication for this approval is advanced solid tumors. This product has also obtained approval from the National Medical Products Administration of the People’s Republic of China in January 2025 to conduct clinical trials in China. AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
